000111692 001__ 111692
000111692 005__ 20240319080959.0
000111692 0247_ $$2doi$$a10.3390/cells11030392
000111692 0248_ $$2sideral$$a127813
000111692 037__ $$aART-2022-127813
000111692 041__ $$aeng
000111692 100__ $$aReina-Ortiz, Chantal
000111692 245__ $$aHarnessing the potential of NK cell-based immunotherapies against multiple myeloma
000111692 260__ $$c2022
000111692 5060_ $$aAccess copy available to the general public$$fUnrestricted
000111692 5203_ $$aNatural killer (NK) cell-based therapies have emerged as promising anticancer treatments due to their potency as cytolytic effectors and synergy with concurrent treatments. Multiple myeloma (MM) is an aggressive B-cell malignancy that, despite development of novel therapeutic agents, remains incurable with a high rate of relapse. In MM, the inhospitable tumor microenvironment prevents host NK cells from exerting their cytolytic function. The development of NK cell immunotherapy works to overcome this altered immune landscape and can be classified in two major groups based on the origin of the cell: autologous or allogeneic. In this review, we compare the treatments in each group, such as autologous chimeric antigen receptor (CAR) NKs and allogeneic off-the-shelf NK cell infusions, and their combinatorial effect with existing MM therapies including monoclonal antibodies and proteasome inhibitors. We also discuss their placement in clinical treatment regimens based on the immune profile of each patient. Through this examination, we would like to discover precisely when each NK cell-based treatment will produce the maximum benefit to the MM patient.
000111692 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-20R$$9info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033$$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-105128RB-I00
000111692 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000111692 590__ $$a6.0$$b2022
000111692 592__ $$a1.537$$b2022
000111692 591__ $$aCELL BIOLOGY$$b60 / 191 = 0.314$$c2022$$dQ2$$eT1
000111692 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2022$$dQ1
000111692 594__ $$a9.0$$b2022
000111692 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000111692 700__ $$aGiraldos, David
000111692 700__ $$aAzaceta, Gemma
000111692 700__ $$aPalomera, Luis
000111692 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo, Isabel$$uUniversidad de Zaragoza
000111692 700__ $$aNaval, Javier
000111692 700__ $$aVillalba, Martín
000111692 700__ $$aAnel, Alberto
000111692 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000111692 773__ $$g11, 3 (2022), 392 [17 pp.]$$pCells$$tCells$$x2073-4409
000111692 8564_ $$s852557$$uhttps://zaguan.unizar.es/record/111692/files/texto_completo.pdf$$yVersión publicada
000111692 8564_ $$s2655210$$uhttps://zaguan.unizar.es/record/111692/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000111692 909CO $$ooai:zaguan.unizar.es:111692$$particulos$$pdriver
000111692 951__ $$a2024-03-18-13:55:45
000111692 980__ $$aARTICLE